Bone

Former U.S. White House Surgeon and FDA Medical Officer joins Bioretec team

Retrieved on: 
Tuesday, May 16, 2023

TAMPERE, Finland, May 16, 2023 /PRNewswire/ -- Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, announces that Dr. Jeremy Dublon joins the Bioretec team to support Company's U.S. commercialization strategy from a clinical and regulatory perspective. Dr. Dublon joins the Bioretec team as a Regulatory Advisor.

Key Points: 
  • Dr. Dublon joins the Bioretec team as a Regulatory Advisor.
  • Dr. Dublon is a board-certified podiatric surgeon specializing in diagnosing and treating conditions in the foot and ankle of people of all ages.
  • Earlier, Dr. Dublon served at the U.S. Food and Drug Administration (FDA) on the review team as a Medical Officer in the Division of Restorative, Repair, and Trauma evaluating orthopedic products.
  • Furthermore, he has served as a Deputy Service Chief at Walter Reed National Military Medical Center, where he led the Podiatry Department and acted as a White House Medical Consultant and Surgeon to the President.

Former U.S. White House Surgeon and FDA Medical Officer joins Bioretec team

Retrieved on: 
Tuesday, May 16, 2023

TAMPERE, Finland, May 16, 2023 /PRNewswire/ -- Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, announces that Dr. Jeremy Dublon joins the Bioretec team to support Company's U.S. commercialization strategy from a clinical and regulatory perspective. Dr. Dublon joins the Bioretec team as a Regulatory Advisor.

Key Points: 
  • Dr. Dublon joins the Bioretec team as a Regulatory Advisor.
  • Dr. Dublon is a board-certified podiatric surgeon specializing in diagnosing and treating conditions in the foot and ankle of people of all ages.
  • Earlier, Dr. Dublon served at the U.S. Food and Drug Administration (FDA) on the review team as a Medical Officer in the Division of Restorative, Repair, and Trauma evaluating orthopedic products.
  • Furthermore, he has served as a Deputy Service Chief at Walter Reed National Military Medical Center, where he led the Podiatry Department and acted as a White House Medical Consultant and Surgeon to the President.

FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis

Retrieved on: 
Monday, May 15, 2023

In addition, due to the serious manifestations of this rare skeletal disorder in children, SIS-101-ADO has been granted Rare Pediatric Disease Designation for the treatment of Autosomal Dominant Osteopetrosis.

Key Points: 
  • In addition, due to the serious manifestations of this rare skeletal disorder in children, SIS-101-ADO has been granted Rare Pediatric Disease Designation for the treatment of Autosomal Dominant Osteopetrosis.
  • FDA Orphan Drug Designation provides SiSaf with incentives such as tax credits for clinical trials, exemption from user fees, and expanded marketplace exclusivity.
  • The Rare Pediatric Disease Designation entitles SiSaf to apply for a priority review voucher that can be used to have the drug approval process expedited by the FDA.
  • SiSaf’s Founder and CEO, Dr. Suzanne Saffie-Siebert, said, “Being granted Orphan Drug Designation and Rare Pediatric Disease Designation is a major milestone in our drive to move our revolutionary siRNA treatment forward to alleviate the pain and suffering that Osteopetrosis ADO2 inflicts.

Why exercising your 'good arm' can also help the one in a sling

Retrieved on: 
Tuesday, May 9, 2023

They are often kept in a sling or cast to immobilise them as a way to promote healing.

Key Points: 
  • They are often kept in a sling or cast to immobilise them as a way to promote healing.
  • It takes a long time to rehabilitate these muscles and muscle strength and function may not be fully restored for some people.

How it works

    • But it is likely associated with neural adaptations in the motor cortex of the brain that controls movement in the body.
    • Researchers have reviewed almost 100 studies and showed the average cross-body transfer ratio between the strength gain in the trained muscle to non-trained muscle ranged from 48% to 77%.
    • And less fatigue is induced during eccentric than other contractions.
    • Resistance exercises – when muscles work against a weight or force – increase muscular strength and endurance using these types of muscle contractions.

What we studied

    • Both eccentric (lengthening) and concentric (shortening) training groups increased muscle strength similarly after the training (by 23 to 26%) for the trained arm.
    • But the non-trained arm showed greater strength increase after eccentric (23%) than concentric training (12%).
    • This tallies with our previous study that showed greater strength gains and cross-education effect from eccentric training.

What to ask your physio

    • This type of training has not been used extensively in rehabilitation so far.
    • Further investigation into the mechanisms at play is needed but our findings could inform changes to how rehabilitation is implemented.

Osteoporosis Awareness and Prevention Month 2023: Healthy Bones Are Always in Style

Retrieved on: 
Monday, May 1, 2023

Inspiration for this year's theme, "Healthy Bones Are Always in Style," was drawn from legendary designer and fashion icon, Iris Apfel.

Key Points: 
  • Inspiration for this year's theme, "Healthy Bones Are Always in Style," was drawn from legendary designer and fashion icon, Iris Apfel.
  • BHOF offers a variety of resources to help individuals learn more about osteoporosis and how to maintain strong and healthy bones.
  • Throughout the month of May, BHOF is also hosting and sharing a variety of events to promote bone health awareness.
  • Thank you to Amgen, Inc., UCB, Inc., and BHOF's individual donors for supporting this May's Osteoporosis Awareness and Prevention Month campaign.

AKC Canine Health Foundation Marks Pet Cancer Awareness Month with Three New Canine Cancer Grants

Retrieved on: 
Monday, May 1, 2023

RALEIGH, N,C., May 1, 2023 /PRNewswire/ -- The AKC Canine Health Foundation (CHF), a non-profit organization dedicated to advancing the health of all dogs, marks Pet Cancer Awareness Month each May to highlight the impact of its funded canine cancer research.

Key Points: 
  • RALEIGH, N,C., May 1, 2023 /PRNewswire/ -- The AKC Canine Health Foundation (CHF), a non-profit organization dedicated to advancing the health of all dogs, marks Pet Cancer Awareness Month each May to highlight the impact of its funded canine cancer research.
  • Already in 2023, CHF has awarded three new grants to study canine lymphoma, anal sac carcinoma, and bone cancer.
  • Therefore, approximately one quarter of CHF's active research portfolio is usually dedicated to studies exploring more accurate diagnostic tests and new treatments for canine cancer.
  • To learn more about the Foundation's commitment to canine cancer research, including educational resources and ways to participate in canine cancer research, please visit akcchf.org/caninecancer .

QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®

Retrieved on: 
Wednesday, April 26, 2023

This new patent in Europe covers the “high purity therapeutic bone agents” technology exclusively licensed to QSAM on a worldwide basis and relates to the novel manner in which the Samarium-153 is produced for use in CycloSam®.

Key Points: 
  • This new patent in Europe covers the “high purity therapeutic bone agents” technology exclusively licensed to QSAM on a worldwide basis and relates to the novel manner in which the Samarium-153 is produced for use in CycloSam®.
  • These types of metastasized bone cancer are the subject of QSAM’s current FDA-cleared Phase 1 clinical trial which is underway and actively enrolling and dosing patients.
  • “This allowance by the EPO marks our second patent in Europe, and we expect to register the patent in multiple individual countries in the EU over the following few weeks, thereby expanding our already established and robust patent estate.
  • More so, this additional IP protection broadens our potential commercial market for what we believe may eventually be a breakthrough therapy for both primary and secondary forms of bone cancer,” added Mr. Baum.

INSIDE INFORMATION: Bioretec updates its product pipeline to accelerate commercialization strategy following the first RemeOs™ FDA market authorization, and consequently updates financial targets

Retrieved on: 
Monday, April 24, 2023

TAMPERE, Finland, April 24, 2023 /PRNewswire/ -- Bioretec Ltd, a pioneer in bioabsorbable orthopedic implants, announced on 30 March 2023 that it had received U.S. market authorization for its RemeOs™ trauma screw from the U.S. Food and Drug Administration (FDA). Following the market authorization, the Board of Directors of Bioretec has today resolved to update and refocus the company's product portfolio to facilitate an accelerated commercialization strategy to provide a more synergistic offering responding to the market demand. Furthermore, Bioretec refines its U.S. go-to-market strategy to fit the company's resources better and provide enhanced possibilities to penetrate the vast U.S. market. Consequently, financial targets are updated to reflect the aforementioned strategic changes.

Key Points: 
  • Furthermore, Bioretec refines its U.S. go-to-market strategy to fit the company's resources better and provide enhanced possibilities to penetrate the vast U.S. market.
  • Additionally, Bioretec is also exploring possibilities to raise additional financing to accelerate the U.S. commercialization of RemeOs™ products, increasing manufacturing capacity, and enhancing product development, spearheaded by the RemeOs™ trauma screw.
  • Bioretec will focus on serving customers in the lower and upper extremities with products that have a faster commercialization strategy and provide a more synergistic offering.
  • To complement the RemeOs™ trauma screw product group, Bioretec has decided to add two new product groups, RemeOs™ staples and RemeOs™ plates to its product development pipeline.

INSIDE INFORMATION: Bioretec updates its product pipeline to accelerate commercialization strategy following the first RemeOs™ FDA market authorization, and consequently updates financial targets

Retrieved on: 
Monday, April 24, 2023

TAMPERE, Finland, April 24, 2023 /PRNewswire/ -- Bioretec Ltd, a pioneer in bioabsorbable orthopedic implants, announced on 30 March 2023 that it had received U.S. market authorization for its RemeOs™ trauma screw from the U.S. Food and Drug Administration (FDA). Following the market authorization, the Board of Directors of Bioretec has today resolved to update and refocus the company's product portfolio to facilitate an accelerated commercialization strategy to provide a more synergistic offering responding to the market demand. Furthermore, Bioretec refines its U.S. go-to-market strategy to fit the company's resources better and provide enhanced possibilities to penetrate the vast U.S. market. Consequently, financial targets are updated to reflect the aforementioned strategic changes.

Key Points: 
  • Furthermore, Bioretec refines its U.S. go-to-market strategy to fit the company's resources better and provide enhanced possibilities to penetrate the vast U.S. market.
  • Additionally, Bioretec is also exploring possibilities to raise additional financing to accelerate the U.S. commercialization of RemeOs™ products, increasing manufacturing capacity, and enhancing product development, spearheaded by the RemeOs™ trauma screw.
  • Bioretec will focus on serving customers in the lower and upper extremities with products that have a faster commercialization strategy and provide a more synergistic offering.
  • To complement the RemeOs™ trauma screw product group, Bioretec has decided to add two new product groups, RemeOs™ staples and RemeOs™ plates to its product development pipeline.

Medacta’s P-Family Hip System offering is now more complete with the introduction of the new SMS Collared Stem

Retrieved on: 
Wednesday, April 19, 2023

The SMS stem is a bone-preserving short femoral stem particularly indicated for patients with good bone quality and narrow femoral canal, classified as Dorr A femurs.

Key Points: 
  • The SMS stem is a bone-preserving short femoral stem particularly indicated for patients with good bone quality and narrow femoral canal, classified as Dorr A femurs.
  • Following the release of the SMS stem in 2017, the new SMS Collared was recently introduced, featuring an optimized collar design with MectaGrip coating on the inferior surface.
  • “The SMS non-collared stem has been a great option for patients with excellent bone quality and Dorr A femoral morphology.
  • The introduction of the SMS Collared stem represents a valuable addition to the P-Family System’s versatility and completeness.